Improving the clarification, characterization, and homogeneity of animal serum through Nanotrap nanoparticle technology

项目摘要 细胞培养技术已经并将继续对生物医学科学的许多领域做出重大贡献 以及有益于人类和动物的研究。在大多数情况下，最低培养基的补充 动物源性产品，例如，动物血清是细胞正常生长所必需的。血清离心 取自家畜的凝结或脱钙全血的液体成分。它提供荷尔蒙 细胞生长和增殖的因子，并提供维持有利的细胞生长和增殖所需的所有基本因子。 成长环境在几种常见的动物血清中，胎牛血清（FBS）应用最广泛 被认为是当前科学研究和发现成功的关键试剂。尽管 虽然FBS被广泛使用，但它也存在许多备受关注的问题;它是异构的，从 很多很多，并且经常被内毒素、支原体、细菌和/或病毒污染。 变异性和污染严重影响实验的重现性和产品的安全性。 需要更好的质量控制方法来消除和检测血清污染物的存在， 特别是从大批量血清中并以高通量的方式。为了满足这一需求， Nanosciences，Inc.设计了一种利用其创新和专有的Nanotrap技术的解决方案， 由可定制的水凝胶微球组成，该微球在其他领域具有广泛的应用性， 靶向、稳定和富集来自生物流体的目标分析物。基于支持性概念验证数据 通过三个具体目标，Ceres提出了第一阶段SBIR，以评估使用Nanotrap的可行性 颗粒，以改善血清中常见污染物的提取和检测，并研究 将Nanotrap技术集成到一个可扩展的、更高通量的工作流程中， 血清批量。如果成功，这项技术的应用可能会显着影响血清 通过以下方式产生：加快满足法规要求所需的处理时间;提高 以检测和去除污染物;以及简化血清收集和销售之间的工作流程。这项工作 然后还将提高该行业使用的血清的整体质量，从而有助于改善这一点。 细胞和组织培养的所有应用的基本资源。

PROJECT SUMMARY Cell culture techniques have, and will continue to, significantly contribute to many of areas of biomedical science and research that will benefit humans and animals. In most cases, the supplementation of minimal culture media with animal-derived products, e.g., animal serum, is essential for proper cell growth. Serum is the centrifuged fluid component of either clotted or defibrinated whole blood taken from domestic cattle. It provides hormone factors for cell growth and proliferation and provides all of the essential factors needed for maintaining a favorable growth environment. Among several common animal sera, fetal bovine serum (FBS) has been the most widely used and is viewed as a critical reagent for the success of current scientific research and discovery. Despite its widespread use, FBS has a number of well-appreciated problems; it is heterogeneous, with great variety from lot to lot, and is frequently contaminated with things like endotoxins, mycoplasma, bacteria, and/or viruses. Variability and contamination significantly affect the reproducibility of experiments and the safety of products. Better quality control methods are needed to eliminate and detect the presence of serum contaminants, especially from large batches of serum and in a high-throughput manner. In response to this need, Ceres Nanosciences, Inc. has devised a solution leveraging its innovative and proprietary Nanotrap technology, which consists of customizable hydrogel microspheres that have widespread applicability in other fields for separating, targeting, stabilizing, and enriching target analytes from biofluids. Based on supporting proof-of-concept data and through three specific aims, Ceres proposes a Phase I SBIR to evaluate the feasibility of using Nanotrap particles to improve the extraction and detection of common contaminants from serum, and to investigate the integration of Nanotrap technology into a scalable, higher-throughput workflow that is able to be used with large- batch volumes of serum. If successful, the application of this technology could significantly impact the way serum is produced by: accelerating the processing time needed to satisfy regulatory requirements; improving the ability to detect and remove contaminants; and streamlining the workflow between serum collection and sale. This work would then also improve the overall quality of serum being used by the industry, thus helping to improve this essential resource for all applications of cell and tissue culture.